235 related articles for article (PubMed ID: 27713795)
1. A survey of Canadian urologists' opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer.
Millar AC; Elterman DS; Goldenberg L; Van Asseldonk B; Curtis A; Jarvi K
Can Urol Assoc J; 2016; 10(5-6):181-184. PubMed ID: 27713795
[TBL] [Abstract][Full Text] [Related]
2. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany.
Kühn CM; Strasser H; Romming A; Wullich B; Goebell PJ
Urol Int; 2015; 95(2):153-9. PubMed ID: 25677365
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
4. Testosterone therapy for men at risk for or with history of prostate cancer.
Morgentaler A
Curr Treat Options Oncol; 2006 Sep; 7(5):363-9. PubMed ID: 16904053
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy following radical prostatectomy.
Khera M; Grober ED; Najari B; Colen JS; Mohamed O; Lamb DJ; Lipshultz LI
J Sex Med; 2009 Apr; 6(4):1165-1170. PubMed ID: 19207277
[TBL] [Abstract][Full Text] [Related]
6. Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial.
Carbunaru S; Sun Z; McCall C; Ofori B; Marshall N; Wang H; Abern M; Liu L; Hollowell CMP; Sharifi R; Vidal P; Kajdacsy-Balla A; Sekosan M; Ferrer K; Wu S; Gallegos M; Gann PH; Moreira D; Sharp LK; Ferrans CE; Murphy AB
Cancer Med; 2023 Oct; 12(19):19690-19700. PubMed ID: 37787097
[TBL] [Abstract][Full Text] [Related]
7. Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy.
Shahine H; Zanaty M; Zakaria AS; Nguyen DD; Couture F; Sadri I; Schwartz R; Arezki A; Elterman D; El-Hakim A; Zorn KC
World J Urol; 2021 Sep; 39(9):3223-3229. PubMed ID: 33034733
[TBL] [Abstract][Full Text] [Related]
8. Testosterone and the Prostate.
Tan RB; Silberstein JL; Hellstrom WJ
Sex Med Rev; 2014 Oct; 2(3-4):112-120. PubMed ID: 27784562
[TBL] [Abstract][Full Text] [Related]
9. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
Jensen CF; Fode M; Østergren P; Sønksen J
Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
[TBL] [Abstract][Full Text] [Related]
10. Androgen replacement in men undergoing treatment for prostate cancer.
Rhoden EL; Averbeck MA; Teloken PE
J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
[TBL] [Abstract][Full Text] [Related]
11. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
Feneley MR; Carruthers M
J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
[TBL] [Abstract][Full Text] [Related]
12. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
14. Post-prostatectomy adjuvant androgen deprivation therapy- Current opinions and practices of Canadian urologists.
Levitt M; Nayak AL; Fergusson DA; Lavallee LT; Morash C; Cagiannos I; Flaman AS; Breau RH
Urol Oncol; 2022 Feb; 40(2):57.e9-57.e14. PubMed ID: 34303596
[TBL] [Abstract][Full Text] [Related]
15. Testosterone therapy and prostate carcinoma.
Rhoden EL; Averbeck MA
Curr Urol Rep; 2009 Nov; 10(6):453-9. PubMed ID: 19863857
[TBL] [Abstract][Full Text] [Related]
16. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
[TBL] [Abstract][Full Text] [Related]
17. Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists.
Gravina GL; Di Sante S; Limoncin E; Mollaioli D; Ciocca G; Carosa E; Sanità P; Di Cesare E; Lenzi A; Jannini EA
Transl Androl Urol; 2015 Apr; 4(2):139-47. PubMed ID: 26816820
[TBL] [Abstract][Full Text] [Related]
18. Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels.
Zhang X; Zhong Y; Saad F; Haider KS; Haider A; Clendenin AG; Xu X
Aging Male; 2020 Jun; 23(2):112-118. PubMed ID: 30857458
[No Abstract] [Full Text] [Related]
19. Testosterone Replacement in Men with Treated and Untreated Prostate Cancer.
Khera M
Sex Med Rev; 2013 Oct; 1(3):143-149. PubMed ID: 27784553
[TBL] [Abstract][Full Text] [Related]
20. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP
Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
